Securities code: 688105 Securities abbreviation: Novozan Announcement No.: 2025-018

Nanjing Nuovezan Biotechnology Co., Ltd

Announcement on the 2025 interim dividend plan

The Board of Directors and all directors of the Company guarantee that the content of this announcement does not contain any false records, misleading statements or statements

and bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

In accordance with the provisions of relevant laws and regulations such as the China Securities Regulatory Commission's Regulatory Guidelines for Listed Companies No. 3 - Cash Dividends of Listed Companies (Revised in 2023), the Listing Rules for Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange (Revised in April 2024), and the Self-Regulatory Guidelines for Listed Companies on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operation (Revised in December 2023), in order to further increase investor returns, To improve the level of investor returns, we will formulate a medium-term dividend plan for 2025 based on the actual situation of the company, as follows:

1. Interim dividend arrangement in 2025

The company intends to pay dividends in the middle of 2025 (including semi-annual and first three quarters), under the premise that the current profit, the accumulated undistributed profit is positive, the company's cash flow can meet the needs of normal operation and sustainable development, and meets other profit distribution conditions stipulated in the articles of association, and the total dividend shall not exceed the net profit attributable to shareholders of the company in the corresponding period.

In order to simplify the dividend procedure, the Board of Directors proposes to the General Meeting of Shareholders to authorize the Board of Directors to handle all matters related to the interim profit distribution in 2025 under the conditions of dividends, including but not limited to deciding whether to distribute profits, formulating profit distribution plans and implementing profit distribution, and the authorization period is from the date of deliberation and approval of the 2024 Annual General Meeting of Shareholders to the date of the 2025 Annual General Meeting of Shareholders of the Company.

2. The decision-making procedures performed by the company

On April 8, 2025, the company held the fifteenth meeting of the second board of directors and the second session of the board of directors

At the thirteenth meeting of the meeting, the "Proposal on the 2025 Interim Dividend Plan" was deliberated and approved, and it was agreed to submit the proposal to the company's 2024 annual general meeting of shareholders for deliberation.

3. Risk Warning

Securities code: 688105 Securities abbreviation: Novozan Announcement No.: 2025-018

The 2025 interim dividend plan still needs to be submitted to the general meeting of shareholders for approval and needs to meet the current dividend conditions before it can be implemented.

The announcement is hereby made.

Nanjing Nuovezan Biotechnology Co., Ltd

board of directors

April 10, 2025